Compare IQV & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IQV | EW |
|---|---|---|
| Founded | 1982 | 1958 |
| Country | United States | United States |
| Employees | 93000 | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.1B | 48.9B |
| IPO Year | 2013 | 1999 |
| Metric | IQV | EW |
|---|---|---|
| Price | $260.43 | $86.05 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 22 | 29 |
| Target Price | ★ $286.79 | $100.96 |
| AVG Volume (30 Days) | 1.3M | ★ 3.1M |
| Earning Date | 10-27-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 4.67 | N/A |
| EPS | ★ 1.61 | 1.07 |
| Revenue | ★ $9,739,000,000.00 | $6,067,600,000.00 |
| Revenue This Year | $6.79 | $11.40 |
| Revenue Next Year | $6.07 | $9.90 |
| P/E Ratio | $164.98 | ★ $81.60 |
| Revenue Growth | ★ 41.60 | 11.55 |
| 52 Week Low | $154.50 | $72.30 |
| 52 Week High | $277.40 | $96.29 |
| Indicator | IQV | EW |
|---|---|---|
| Relative Strength Index (RSI) | 48.42 | 44.74 |
| Support Level | $252.53 | $83.49 |
| Resistance Level | $274.60 | $86.50 |
| Average True Range (ATR) | 7.27 | 2.01 |
| MACD | -1.99 | -0.04 |
| Stochastic Oscillator | 14.24 | 30.39 |
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.